Announcements Trials
Browse Landscape

Status

Completed 25Active not recruiting 12Withdrawn 8Terminated 7Recruiting 7No longer available 4Unknown 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Expanded_access 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4

Interventions

trametinib 4nilotinib 4elotuzumab 4dabrafenib 4Amifampridine 4regorafenib 3pembrolizumab 3midostaurin 3fludarabine phosphate 3fludarabine 3Nivolumab 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Cyclophosphamide 3Crizotinib 3Bortezomib 3Axitinib 3venetoclax 2veliparib 2tazemetostat 2talimogene laherparepvec 2navitoclax 2gallium 68 PSMA-11 2ceritinib 2carbon-11 acetate 2aldesleukin 2Whole-Body Irradiation 2Trabectedin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
No longer available × elotuzumab × Clear all
NCT02856438 2023-12-19

Early Patient Access Treatment Use Protocol CA204-220

Bristol-Myers Squibb

No longer available
Plasma cell

Multiple Myeloma

NCT02368301 2023-11-30

Expanded Access Treatment Protocol CA204-143

Bristol-Myers Squibb

No longer available
Plasma cell

Multiple Myeloma

NCT03126617 2021-11-29

Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma

Bristol-Myers Squibb

No longer available
Plasma cell

Multiple Myeloma

NCT02541643 2015-09-04

Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma

Icahn School of Medicine at Mount Sinai

No longer available
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡